An in-depth study on the patent litigation in Pharma & Biotech industry in 2014.
See who were the top defendants and the top plaintiffs. Patent litigation suits filed by year, by court, by law-firms, by region, etc.
A presentation by Jim Dahl, retired Assistant Director FDA's Office of Criminal Investigations and Partnership for Safe Medicines Board Member, about the threat of imported counterfeit prescription drugs.
A presentation by J. Aaron Graham, Executive Director of Brand Safety & Security at Boehringer Ingelheim Pharmaceuticals, Inc., about the threat of imported counterfeit prescription drugs.
A presentation by Tom T. Kubic, President and CEO, Pharmaceutical Security Institute and Treasurer, Partnership for Safe Medicines about the threat of imported counterfeit prescription drugs.
Linda I. Marks, Senior Litigation Counsel, Consumer Protection Branch, U.S. Department of Justice speaks around criminal prosecutions of drug counterfeiters and diverters in the US.
Medical records have a major role to play in various legal and medical contexts because it is the information in them that decides the course of a case.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
A presentation by Jim Dahl, retired Assistant Director FDA's Office of Criminal Investigations and Partnership for Safe Medicines Board Member, about the threat of imported counterfeit prescription drugs.
A presentation by J. Aaron Graham, Executive Director of Brand Safety & Security at Boehringer Ingelheim Pharmaceuticals, Inc., about the threat of imported counterfeit prescription drugs.
A presentation by Tom T. Kubic, President and CEO, Pharmaceutical Security Institute and Treasurer, Partnership for Safe Medicines about the threat of imported counterfeit prescription drugs.
Linda I. Marks, Senior Litigation Counsel, Consumer Protection Branch, U.S. Department of Justice speaks around criminal prosecutions of drug counterfeiters and diverters in the US.
Medical records have a major role to play in various legal and medical contexts because it is the information in them that decides the course of a case.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
Country study: Availability of essential medicines Arete-Zoe, LLC
WHO list of 427 essential medicines was compared to medicinal products available in the Czech Republic. The dataset was downloaded from national database of medicinal products on December 30, 2016. Of the 427 essential medicines defined by WHO, 135 are currently unavailable in the Czech Republic. Most affected ATC groups are antiparasitics, antiinfectives, and dermatologicals. For more information contact Arete-Zoe directly.
The availability of Essential Medicines in Hungary shows summary tables that compare the World Health Organization Essential Medicines List (WHO EML) with the National Substitution List (NL) by system organ class. The graphs are color-coded for more natural orientation: WHO EML products are marked blue, NL products are green, and products included in both lists are yellow. Many registrations include the number of individual drug forms, including package sizes and dosage forms, rather than a single registration number. This is because different dosage forms may have different indications. Drugs are categorized by ATC Code; that means some active ingredients are listed in all relevant forms and system organ classes. The dataset is presented as a summary and then in detail by organ class and ATC subclass as relevant/appropriate. The focus of the following analysis is on essential medicines that are not available in Hungary, and evaluation of the situation in the context of public health needs and global drug shortages. To this end, the Essential List of Medicines defined by the World Health Organization (WHO) is compared to the Substitution List, which can be found on the website of The National Institute of Pharmacy and Nutrition.
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs -Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
Dave Aronberg: "Profiteers of Tragedy: Making Money Off America’s Opioid Addi...reportingonhealth
Dave Aronberg's slides from the Center for Health Journalism webinar, "Profiteers of Tragedy: Making Money Off America’s Opioid Addicts," 10.31.17
More info: https://www.centerforhealthjournalism.org/content/profiteers-tragedy-making-money-americas-opioid-addicts
The Skeeterhawk Experiment 2013 Slide Presentation (Prescription Drug Misuse)Skeeterhawk
The Skeeterhawk Experiment was organized in March 2013 to help end the scourge of prescription drug misuse through the testing of innovative prevention, treatment, and overdose rescue strategies in real-life communities, beginning in Northeast Florida. Utilizing data gathered from a multitude of reliable sources, The Skeeterhawk Experiment believes it is possible for every community to devise targeted, data-driven strategies to tackle its unique set of prescription drug misuse problems. This is the organization's Northeast Florida community presentation for 2013.
Baby Steps of Competition Law Jurisprudence in Pharmaceutical Sector - K.K. S...KK SHARMA LAW OFFICES
November and December 2016 have seen a good number of orders by COMPAT. It was a culmination of a large number of hearings in the preceding months. One of the orders passed by COMPAT in concluding month of preceding year was in
pharmaceutical sector. Although only one order but it disposed of more than one appeals pending before COMPAT. Despite being voluminous, this order barely goes into the details of the issues. Only two aspects- poor investigation and
mechanical acceptance of the report by the Commission-proved to be the nemesis of all the labour and deliberations of the lower authorities for more than four years.
The order, once again (as if it was needed ), etches in bold relief the basic dictum that ‘principles of natural justice’ are inviolable. What this COMPAT order says is that unless investigation is up to the mark and if the investigation which is not up to the mark is not made up to the mark by the Commission by using is authority, there is hardly any future for any outcome arising from such deliberations.
The author who not only was closely involved in drafting of regulations for the functioning of the Commission but also developed the Antitrust Division of CCI to successfully deal with the reports of DG and take it to logical conclusion discusses the order passed by COMPAT.
To recap the previous month's pharma highlights to Pharma Uptoday followers, Monthly magazine Volume 17 has been released with the following content.
News Uptoday
New Guidance
Audit Findings
483 Observations
EU Non Compliance Report
- INTEGRA LIFE SCIENCES CORP, United States
- JINAN JINDA PHARMACEUTICAL CHEMISTRY CO., LTD., China
- WUXI JIDA PHARMACEUTICAL CO., LTD, China
- PARABOLIC DRUGS LIMITED, India
Warning Letters
- Mahendra Chemicals, India
Regulations of the Month
- Sec. 211.25 Personnel qualifications
- Sec. 211.28 Personnel responsibilities
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Sathish Vemula
News Uptoday
New Guidance
Audit Findings
- Diabetes Corporation of America
- Pine Pharmaceuticals
Warning Letters
- Warning letter: American Family Pharmacy
- Warning letter: Dr. Reddy's Laboratories Limited
- Warning letter: Sandoz Private Limited
Article of the Month
- Data Integrity Checklist related to Electronic Records and Electronic Signatures.
Regulations of the Month
- Sec. 211.46 Ventilation, air filtration, air heating and cooling
- Sec. 211.48 Plumbing
Talc is a main ingredient in Johnson & Johnson baby powder. The U.S. Food and Drug Administration classifies talc as a cosmetic. Cosmetics are regulated less stringently by the FDA.
3 News Uptoday
22 New Guidance
28 Audit Findings
483 Observations
- Caraco Pharmaceutical Laboratories
- Hospira Inc
- Novartis Consumer Health
- McNeil Consumer Healthcare
Warning Letters
- Hikma Farmaceutica, (Portugal) S.A.
- Cadila Pharmaceuticals Limited
- Sharp Global Limited
- Wells Pharmacy Network LLC
EMA Non-Compliance Reports
- Taishan City Chemical Pharmaceutical Co. Ltd., China
- Zhejiang Apeloa Kangyu Bio-Pharmaceutical Co. Ltd., China
- MANUEL RIESGO S.A., Spain
- Ranbaxy Laboratories Limited, Dewas, India
36 Regulations of the Month
§ 211.186 Master production and control records
§ 211.188 Batch production and control records
In this presentation, Director of National Outreach Shabbir Imber Safdar reviews the current state of counterfeit drugs in America today, discusses some of the myths surrounding importation, and provides tips for saving money safely on the cost of prescription drugs.
ICIC 2014 Patent Landscape Analysis as a Tool for Public Policies Adjustment:...Dr. Haxel Consult
The innovative multinational pharmaceutical industry is highly dependent on the release and promotion of new drugs. However, recent economic evidence demonstrates a continuing decrease in new drugs’ market approval. Moreover, the industry is challenged by the “patent cliff”, where many blockbuster drugs are losing patent protection and facing ferocious competition.
It seems that the shortage of new drugs points to an intensification of drug development based on molecules already known, leading to incremental patents. However, there is a suspicion that many incremental patents are actually trivial, because they add little or nothing to existing therapies, but still impose high drug costs. To analyze that hypothesis, the present study has drawn the profile of all patents filed in Brazil in the antiretroviral (ARV) field up to 2012. Using VantagePoint® and Questel Orbit® softwares, a patent matrix was constructed with quali-quantitative data. Next, the patent applications' claims were analysed in order to detect incremental patents and classified according to their incrementalities. Finally we looked for evidence of triviality. As a result, it was demonstrated that the ARV market is highly concentrated and patent applications basically belong to six countries. Evidence that many incrementalities are actually trivialities and act as entry barriers, was found. Patent landscape studies such as this one can be extrapolated to other areas or countries, and can be used as a tool for public policy’s analysis to really fuel technological advance.
June 14, 2018 presentation to the San Diego Regulatory Affairs Network (SDRAN) Regulatory Affairs Certification (RAC) Review Course on the basics of FDA regulation of generic drugs and biosimilars.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Country study: Availability of essential medicines Arete-Zoe, LLC
WHO list of 427 essential medicines was compared to medicinal products available in the Czech Republic. The dataset was downloaded from national database of medicinal products on December 30, 2016. Of the 427 essential medicines defined by WHO, 135 are currently unavailable in the Czech Republic. Most affected ATC groups are antiparasitics, antiinfectives, and dermatologicals. For more information contact Arete-Zoe directly.
The availability of Essential Medicines in Hungary shows summary tables that compare the World Health Organization Essential Medicines List (WHO EML) with the National Substitution List (NL) by system organ class. The graphs are color-coded for more natural orientation: WHO EML products are marked blue, NL products are green, and products included in both lists are yellow. Many registrations include the number of individual drug forms, including package sizes and dosage forms, rather than a single registration number. This is because different dosage forms may have different indications. Drugs are categorized by ATC Code; that means some active ingredients are listed in all relevant forms and system organ classes. The dataset is presented as a summary and then in detail by organ class and ATC subclass as relevant/appropriate. The focus of the following analysis is on essential medicines that are not available in Hungary, and evaluation of the situation in the context of public health needs and global drug shortages. To this end, the Essential List of Medicines defined by the World Health Organization (WHO) is compared to the Substitution List, which can be found on the website of The National Institute of Pharmacy and Nutrition.
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs -Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
Dave Aronberg: "Profiteers of Tragedy: Making Money Off America’s Opioid Addi...reportingonhealth
Dave Aronberg's slides from the Center for Health Journalism webinar, "Profiteers of Tragedy: Making Money Off America’s Opioid Addicts," 10.31.17
More info: https://www.centerforhealthjournalism.org/content/profiteers-tragedy-making-money-americas-opioid-addicts
The Skeeterhawk Experiment 2013 Slide Presentation (Prescription Drug Misuse)Skeeterhawk
The Skeeterhawk Experiment was organized in March 2013 to help end the scourge of prescription drug misuse through the testing of innovative prevention, treatment, and overdose rescue strategies in real-life communities, beginning in Northeast Florida. Utilizing data gathered from a multitude of reliable sources, The Skeeterhawk Experiment believes it is possible for every community to devise targeted, data-driven strategies to tackle its unique set of prescription drug misuse problems. This is the organization's Northeast Florida community presentation for 2013.
Baby Steps of Competition Law Jurisprudence in Pharmaceutical Sector - K.K. S...KK SHARMA LAW OFFICES
November and December 2016 have seen a good number of orders by COMPAT. It was a culmination of a large number of hearings in the preceding months. One of the orders passed by COMPAT in concluding month of preceding year was in
pharmaceutical sector. Although only one order but it disposed of more than one appeals pending before COMPAT. Despite being voluminous, this order barely goes into the details of the issues. Only two aspects- poor investigation and
mechanical acceptance of the report by the Commission-proved to be the nemesis of all the labour and deliberations of the lower authorities for more than four years.
The order, once again (as if it was needed ), etches in bold relief the basic dictum that ‘principles of natural justice’ are inviolable. What this COMPAT order says is that unless investigation is up to the mark and if the investigation which is not up to the mark is not made up to the mark by the Commission by using is authority, there is hardly any future for any outcome arising from such deliberations.
The author who not only was closely involved in drafting of regulations for the functioning of the Commission but also developed the Antitrust Division of CCI to successfully deal with the reports of DG and take it to logical conclusion discusses the order passed by COMPAT.
To recap the previous month's pharma highlights to Pharma Uptoday followers, Monthly magazine Volume 17 has been released with the following content.
News Uptoday
New Guidance
Audit Findings
483 Observations
EU Non Compliance Report
- INTEGRA LIFE SCIENCES CORP, United States
- JINAN JINDA PHARMACEUTICAL CHEMISTRY CO., LTD., China
- WUXI JIDA PHARMACEUTICAL CO., LTD, China
- PARABOLIC DRUGS LIMITED, India
Warning Letters
- Mahendra Chemicals, India
Regulations of the Month
- Sec. 211.25 Personnel qualifications
- Sec. 211.28 Personnel responsibilities
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Sathish Vemula
News Uptoday
New Guidance
Audit Findings
- Diabetes Corporation of America
- Pine Pharmaceuticals
Warning Letters
- Warning letter: American Family Pharmacy
- Warning letter: Dr. Reddy's Laboratories Limited
- Warning letter: Sandoz Private Limited
Article of the Month
- Data Integrity Checklist related to Electronic Records and Electronic Signatures.
Regulations of the Month
- Sec. 211.46 Ventilation, air filtration, air heating and cooling
- Sec. 211.48 Plumbing
Talc is a main ingredient in Johnson & Johnson baby powder. The U.S. Food and Drug Administration classifies talc as a cosmetic. Cosmetics are regulated less stringently by the FDA.
3 News Uptoday
22 New Guidance
28 Audit Findings
483 Observations
- Caraco Pharmaceutical Laboratories
- Hospira Inc
- Novartis Consumer Health
- McNeil Consumer Healthcare
Warning Letters
- Hikma Farmaceutica, (Portugal) S.A.
- Cadila Pharmaceuticals Limited
- Sharp Global Limited
- Wells Pharmacy Network LLC
EMA Non-Compliance Reports
- Taishan City Chemical Pharmaceutical Co. Ltd., China
- Zhejiang Apeloa Kangyu Bio-Pharmaceutical Co. Ltd., China
- MANUEL RIESGO S.A., Spain
- Ranbaxy Laboratories Limited, Dewas, India
36 Regulations of the Month
§ 211.186 Master production and control records
§ 211.188 Batch production and control records
In this presentation, Director of National Outreach Shabbir Imber Safdar reviews the current state of counterfeit drugs in America today, discusses some of the myths surrounding importation, and provides tips for saving money safely on the cost of prescription drugs.
ICIC 2014 Patent Landscape Analysis as a Tool for Public Policies Adjustment:...Dr. Haxel Consult
The innovative multinational pharmaceutical industry is highly dependent on the release and promotion of new drugs. However, recent economic evidence demonstrates a continuing decrease in new drugs’ market approval. Moreover, the industry is challenged by the “patent cliff”, where many blockbuster drugs are losing patent protection and facing ferocious competition.
It seems that the shortage of new drugs points to an intensification of drug development based on molecules already known, leading to incremental patents. However, there is a suspicion that many incremental patents are actually trivial, because they add little or nothing to existing therapies, but still impose high drug costs. To analyze that hypothesis, the present study has drawn the profile of all patents filed in Brazil in the antiretroviral (ARV) field up to 2012. Using VantagePoint® and Questel Orbit® softwares, a patent matrix was constructed with quali-quantitative data. Next, the patent applications' claims were analysed in order to detect incremental patents and classified according to their incrementalities. Finally we looked for evidence of triviality. As a result, it was demonstrated that the ARV market is highly concentrated and patent applications basically belong to six countries. Evidence that many incrementalities are actually trivialities and act as entry barriers, was found. Patent landscape studies such as this one can be extrapolated to other areas or countries, and can be used as a tool for public policy’s analysis to really fuel technological advance.
June 14, 2018 presentation to the San Diego Regulatory Affairs Network (SDRAN) Regulatory Affairs Certification (RAC) Review Course on the basics of FDA regulation of generic drugs and biosimilars.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Partner Michael Fuller wrote an article for the Bloomberg BNA - Pharmaceutical Law & Industry Report discussing how the PTAB may be taking a more balanced approach in biotech and pharmaceutical IPRs.
Data integrity - Regulatory Perspective and Challenges: santoshnarla
Data Integrity: Regulatory Perspective and Challenges.
This presentation will present the importance of data integrity in the pharma industry with regards to the quality compliance and its impact on industry. This presentation also emphasizes on importance of regulatory affairs department in ensuring the data integrity and regulatory challenges.
Expert witness view of fda regulated companies - information trial attorneys ...Joshua Sharlin, Ph.D.
1. Learn an expert witness’s view about common problems and errors in the processes FDA requires
2. Understand how information is collected and reported in today’s FDA-regulated environment
3. Identify documents that add to a knowledgebase about the activities and results of FDA-regulated processes
June 24, 2015 Presentation to the Regulatory Affairs Certification (RAC) Test Review Course sponsored by the San Diego Regulatory Affairs Network, with a focus on regulation of ANDAs, OTC drugs, and Orphan Drugs, covering these issues relating to generic drugs:
♦ Basics
♦ User Fees
♦ Power
♦ Addressing Abuses – by Rule & Statute
♦ Biosimilars – Basics of New Law
Similar to Pharma & Biotech - Patent Litigation Report 2014 - MaxVal Group, Inc (20)
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
5. Pharma & Biotech patent litigation analysis 5
0
5
10
15
20
25
30
35
40
45
50
Top plaintiff No. of cases
Novartis Pharmaceuticals Corp. 47
Otsuka Pharmaceutical Co., Ltd. 35
AstraZeneca AB 32
Pfizer, Inc. 30
The Tawnsaura Group, LLC 26
AbbVie, Inc. 22
Cephalon, Inc. 22
Thermolife International, LLC 22
Warner Chilcott Company, LLC 21
Eli Lilly and Company 19
TOP COMPANIES AS PLAINTIFF
6. Pharma & Biotech patent litigation analysis 6
0
5
10
15
20
25
30
35
40
45
Top defendant No. of cases
Mylan, Inc. 43
Watson Laboratories, Inc. 35
Actavis Elizabeth, LLC 30
Lupin, Ltd. 28
Sandoz, Inc. 26
Apotex Corp. 24
Amneal Pharmaceuticals, LLC 23
Par Pharmaceutical, Inc. 22
Aurobinda Pharma, Ltd. 19
Roxane Laboratories, Inc. 18
TOP COMPANIES AS DEFENDANT
7. Pharma & Biotech patent litigation analysis 7
Following are the details of the court wise case filings by Pharma & Biotech companies in the year 2014
0
50
100
150
200
250
California
Central
California
Northern
Delaware Florida
Southern
Illinois
Northern
Indiana
Southern
Massachu
setts
Michigan
Eastern
New
Jersey
New York
Southern
Texas
Eastern
West
Virginia
Northern
Utah Rest of
the
Courts
No. of Cases 18 7 216 10 11 12 10 10 156 29 9 11 12 73
3%
1%
37%
2% 2% 2% 2% 2%
27%
5%
1% 2% 2%
12%
COURT-WISE NEW CASES FILED IN 2014
8. Pharma & Biotech patent litigation analysis 8
Following are the details of the court wise case closures by Pharma & Biotech companies in the year 2014
0
20
40
60
80
100
120
140
160
180
California
Central
California
Northern
California
Southern
Delaware Florida
Southern
Illinois
Northern
Indiana
Southern
Massachu
setts
Nevada New
Jersey
New York
Southern
Virginia
Eastern
Texas
Eastern
Rest of
the
Courts
No. of Cases 50 13 19 162 11 10 8 13 8 113 40 43 23 92
8%
2%
3%
27%
2% 2% 1%
2%
1%
19%
7% 7%
4%
15%
COURT-WISE CLOSED CASES IN 2014
9. Pharma & Biotech patent litigation analysis 9
0
50
100
150
200
250
300
350
400
450
2014 Filed 2014 Closed
Midwest 51 45
Northeast 422 341
South East 53 86
South West 16 34
West 42 99
REGION-WISE FILED & CLOSED CASES IN 2014
10. Pharma & Biotech patent litigation analysis 10
0
20
40
60
80
100
120
140
160
180
200
Top Plaintiff Lawfirm 2014 cases
0
5
10
15
20
25
30
35
Top Defendant Lawfirm 2014 cases
Plaintiff's Lawfirm No. of cases
Morris, Nichols, Arsht & Tunnell, LLP 177
Mccarter & English, LLP 92
Pepper Hamilton, LLP 55
Ashby & Geddes 25
Saul Ewing, LLP 23
Shaw Keller, LLP 22
Fish & Richardson, PC 21
Newport Trial Group 19
Barnes & Thornburg, LLP 18
Robinson, Wettre & Miller, LLC 17
Defendant's Lawfirm No. of cases
Potter Anderson & Corroon, LLP 31
Richards, Layton & Finger, PA 22
Young Conaway Stargatt & Taylor, LLP 19
Budd Larner, PC 15
Phillips, Goldman & Spence, PA 14
Connell Foley, LLP 13
Fish & Richardson, PC 9
Fox Rothschild, LLP 9
Hill Wallack, LLP 8
Saiber, LLC 8
TOP LAWFIRMS HANDLING PHARMA & BIOTECH LAWSUITS
11. Pharma & Biotech patent litigation analysis 11
Please contact us at bd@maxval-ip.com for detailed/comprehensive reports which
will also include the following analysis:
• Outcome of closed cases
• Settlements
• Judgments
• Dismissals
• Transfer of cases
• Damages
• Injunctions
• Winning and losing party
• Cases appealed in Federal Circuit (CAFC)
• ITC case details
• Supreme court case details
CONTACT US FOR DETAILED ANALYSIS
12. Pharma & Biotech patent litigation analysis 12
MaxVal’s Patent Litigation Databank, Analytics & API
Litigation databank contains patent litigations filed since 1980.
67,000+ cases in databank with daily updates.
Fully searchable databases with information related to patent litigation from ECFs, PACER, ITC, etc.
Complaints, docket reports, patent, product details, and patent file histories.
Watch Case by patent, product, party, inventor etc.
Outcome of the closed cases, such as settlements, dismissals, judgments etc.
Litigation daily alerts.
Patent litigation data analytics & research services.
API - Integrate litigation data to your internal patent database/tools for analytics purpose and mapping of
litigation information to your study.
DATA SOURCE
13. Pharma & Biotech patent litigation analysis
MaxVal Group, Inc.
2251 Grant Road, Los Altos, CA 94024
Phone: 650-472-0644 Fax: 650-625-0294
Email: bd@maxval.com Web: www.maxval.com
SEEWhat Else We Can Do For
YOU
13
Need the full report?
(or)
Similar reports on patent litigation of your interest?
Please contact us at bd@maxval.com